CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 30 enrolled
Drug / intervention
Placebo +1 moredrug
Likely dose
OROS-methylphenidate 18 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00530257
NCT00530257Phase 4Completed
CompareCT.gov

Effect of OROS-Methylphenidate (Concerta) on Different Domains of Attention and Working Memory in Children With Attention-Deficit/Hyperactivity Disorder

Children's Hospital of Philadelphia·interventional·Posted Sep 17, 2007·Updated Dec 19, 2011

In Brief

A Phase 4 clinical trial evaluating Placebo and OROS-methylphenidate for Attention Deficit Hyperactivity Disorder. Completed, enrolled 30 participants across 1 site.

Detailed Summary

This study investigates whether OROS-methylphenidate improves performance on different aspects of attention and memory in children with Attention-Deficit Hyperactivity Disorder (ADHD).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAttention Deficit Hyperactivity Disorder
CountriesUnited States
CollaboratorsOrtho-McNeil Janssen Scientific Affairs, LLC

Timeline

Phase 4CompletedFinished
200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedSep 17, 2007
Enrollment StartJun 1, 2004
Primary CompletionJun 1, 2008
TodayJul 2, 2026
Enrollment to primary: 4 yearsPosted 18.8 years ago

Interventions

Placebodrug

Placebo (sugar pill)

OROS-methylphenidatedrug

18 mg to 54 mg once a day for 1 week